ClinicalTrials.gov
public full text
Public Domain
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy versus observation in patients (pts) with aggressive CD20+ B-cell lymphoma and mantle cell lymphoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma#898781
- Rituximab in Treating Patients With Hodgkin's Lymphoma#865614
- Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma#1171684
- Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma#1058715
- Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma#859051
Record · ID 1197406
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive